# Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI

> **NCT07181499** · PHASE2 · RECRUITING · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 28 (estimated)

## Conditions studied

- NSCLC
- Adjuvant Drug Therapy
- EGFR

## Interventions

- **DRUG:** Befotertinib
- **DRUG:** Pemetrexed + Carboplatin

## Key facts

- **NCT ID:** NCT07181499
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2028-11
- **Final completion:** 2028-12
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07181499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07181499, "Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07181499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*